Free Trial
NASDAQ:PRLD

Prelude Therapeutics Q4 2024 Earnings Report

Prelude Therapeutics logo
$0.86 -0.02 (-2.45%)
As of 04/24/2025 04:00 PM Eastern

Prelude Therapeutics EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.49
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Prelude Therapeutics Revenue Results

Actual Revenue
$4.00 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Prelude Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 10, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Prelude Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Prelude Therapeutics Earnings Headlines

Prelude Therapeutics Founder Acquires 28% More Stock
Prelude Therapeutics CEO buys $467K in common stock
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Prelude Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prelude Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prelude Therapeutics and other key companies, straight to your email.

About Prelude Therapeutics

Prelude Therapeutics (NASDAQ:PRLD), a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

View Prelude Therapeutics Profile

More Earnings Resources from MarketBeat